Skip to content

Single‐dose psilocybin superior to placebo for MDD in community setting

The Brown University Psychopharmacology Update November 14, 2026 DOI: 10.1002/pu.31520 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Peer reviewed
Topics Depression Psilocybin
Key points States that major depressive disorder affects about 300 million people worldwide and that about one-third of these have treatment-resistant depression, commonly defined as failure to respond to two antidepressants; notes that access to specialized treatments is limited.

Abstract

Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.

Explore topics